CPT1A and metabolic dysfunction-associated steatotic liver disease: Besides, the expressions of Cpt1a, Acadm, Hadhb and Eci2 were up-regulated after SCO administration (Figure 6B), suggesting that SCO inhibit the progression of NAFLD may be closely related to regulating the process of fatty acid (triglyceride) synthesis and degradation.